Aeterna Wealth
Sectoral/Thematic · Direct plan · Growth

Bajaj Finserv Healthcare Fund (Direct)

Bajaj Finserv Mutual Fund · benchmark Nifty 500 TRI · 1.8 years old · AMFI code 153157

–
Track-record rating

Not rated yet: a rating needs at least 3 years of history (1 year for index funds).

Returns against the index

PeriodFundIndex (TRI)DifferenceRank in category
6 months19.4%2.5%+16.9%2 / 17
1 year21.0%-1.0%+22.0%7 / 16
3 years (a year)––––
5 years (a year)––––

Growth option, point to point to 5 Nov 2026; periods over a year are annualised (CAGR). Index returns use the total-return index, which includes dividends.

Risk

Portfolio

Divi's Laboratories Limited9.8%
Sun Pharmaceutical Industries Limited9.0%
Piramal Pharma Limited6.4%
Rubicon Research Limited6.1%
Aurobindo Pharma Limited6.0%
Apollo Hospitals Enterprise Limited5.5%
Torrent Pharmaceuticals Limited4.8%
Emcure Pharmaceuticals Limited4.0%
Laurus Labs Limited3.9%
Neuland Laboratories Limited3.8%

Top 10 holdings, September 2026 portfolio.

Common questions

What is the NAV of Bajaj Finserv Healthcare Fund (Direct plan)?

₹12.20 on 5 Nov 2026 (Growth option).

What is the expense ratio of Bajaj Finserv Healthcare Fund (Direct)?

0.90% a year; the Regular plan's is 2.59%.

What does Bajaj Finserv Healthcare Fund invest in?

Its largest holdings are Divi's Laboratories Limited, Sun Pharmaceutical Industries Limited, Piramal Pharma Limited, with 33 stocks in all (September 2026 portfolio).

Data as of 5 Nov 2026: NAVs from AMFI, index data from NSE Indices, portfolios from Bajaj Finserv Mutual Fund's monthly disclosure. Updated every weekday. Read the scheme documents before investing.